Med Ed Report briefs: April 2013

Share this article:
Med Ed Report briefs: April 2013
Med Ed Report briefs: April 2013

Pri-Med and the American College of Physicians (ACP) said they were awarded a grant by the REMS Program Companies to develop and implement a program to educate clinicians about safety and efficacy when prescribing opioids.

Exhibitor magazine's 2013 Economic Outlook Survey says exhibitors  hope this year's returns will improve on those for 2012. While 2013 trade show budgets are down for 24% of exhibitors, the survey showed budgets are up for 30%, and 46% are maintaining last year's allocations.

Boehringer Ingelheim, which markets anticoagulant Pradaxa, said it's working with the American College of Cardiology and the Chinese Society of Cardiology on an AFib educational program for docs in China.

Compliance services firm QPharma is offering a Sunshine Act e-learning course for life science firms. The online course summarizes the act, emphasizes its key concepts, and outlines requirements for reporting aggregate spend.

Elsevier's CME office said it will partner with  AcademicCME and ArcheMedX to deliver online CME programs powered by the ArcheMedX Learning Architecture, an informatics-driven, connected learning platform.
Share this article:
close

Next Article in Agency Gallery

Email Newsletters

More in Agency Gallery

Private View: Creating Compelling Experiences

Private View: Creating Compelling Experiences

In today's multi-channel environment, game-changing ideas blend creativity and sensory ideation to create a meaningful customer experience

Putting consumers at the center of your universe

Putting consumers at the center of your universe

The question should be: How do you simplify and identify the moments that mean the most to customers?

Did "pay-to-play" confab help Zohydro approval?

Did "pay-to-play" confab help Zohydro approval?

US senators Joe Manchin (D-WV) and David Vitter (R-LA) are asking whether a "pay-to-play" meeting between drug industry executives and FDA officials influenced the agency's approval of Zohydro